Chinese Scientists Achieve 14 Million-Fold Expansion of Cancer-Fighting NK Cells from Single Stem Cell
核心洞察
Chinese Academy of Sciences researchers developed a breakthrough method to generate up to 14 million induced NK cells or 7.6 million CAR-iNK cells from a single cord blood stem cell, representing a massive scaling advance for cancer (搜索) immunotherapy manufacturing.
The innovative three-stage process engineers CD34+ (搜索) hematopoietic stem cells before maturation, reducing viral vector requirements by up to 600,000-fold compared to traditional mature NK cell modification approaches.
Laboratory testing demonstrated that the engineered CAR-iNK cells effectively reduced tumor growth and extended survival in mouse models of B-cell acute lymphoblastic leukemia (搜索), with one-fifth of a cord blood unit potentially yielding thousands of treatment doses.
Chinese researchers have achieved a major breakthrough in cancer (搜索) immunotherapy manufacturing by developing a method that can generate up to 14 million tumor-killing natural killer (NK) cells from a single stem cell, potentially revolutionizing the scalability and cost-effectiveness of CAR-NK cell therapy.
The research team, led by Professor Jinyong Wang at the Institute of Zoology of the Chinese Academy of Sciences, published their findings in Nature Biomedical Engineering, demonstrating a novel approach that addresses key manufacturing challenges that have limited the clinical application of CAR-NK therapies.
Revolutionary Stem Cell Engineering Approach
Traditional CAR-NK therapy approaches rely on mature NK cells collected from peripheral blood or cord blood, presenting significant obstacles including wide variability between cells, limited efficiency during genetic modification, high production costs, and lengthy preparation times. The Chinese team developed a fundamentally different strategy by starting with CD34+ (搜索) hematopoietic stem and progenitor cells (HSPCs) from cord blood rather than mature NK cells.
"Instead of editing grown NK cells, the CAS group started with early blood-forming stem and progenitor cells taken from cord blood," the researchers explained. This early-stage genetic engineering allows cells to copy the new gene as they divide, ensuring more descendants carry the same modification.
The team's three-stage manufacturing process begins with expanding CD34+ (搜索) HSPCs using irradiated AFT024 feeder cells, achieving an 800- to 1,000-fold multiplication within 14 days. The expanded cells are then cultured with OP9 feeder cells to create artificial hematopoietic organoid aggregates that support efficient NK lineage commitment and development. In the final stage, committed NK cells mature and multiply further, producing highly pure induced NK (iNK) or CAR-iNK cells expressing endogenous CD16 (搜索).
Unprecedented Cell Yield and Cost Reduction
The manufacturing breakthrough achieved remarkable efficiency metrics. A single CD34+ (搜索) HSPC generated as many as 14 million iNK cells or 7.6 million CAR-iNK cells. The researchers estimate that one-fifth of a typical cord blood unit could theoretically yield enough cells for thousands or even tens of thousands of treatment doses.
Perhaps equally significant is the dramatic reduction in viral vector requirements for CAR engineering. Compared to the amount typically needed to modify mature NK cells, this method used only approximately 1/140,000 (by Day 42 of culture) to 1/600,000 (by Day 49) as much viral vector, representing substantial cost savings for manufacturing.
Strong Anti-Tumor Activity in Preclinical Models
Laboratory testing validated the therapeutic potential of the engineered cells. Both iNK and CAR-iNK cells demonstrated powerful tumor-killing ability in controlled studies. In cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) mouse models of human B-cell acute lymphoblastic leukemia (搜索) (B-ALL), CD19 (搜索) CAR-iNK cells reduced tumor growth and extended animal survival.
The engineered cells maintained their cancer (搜索)-fighting capabilities even after freezing and thawing, suggesting clinics could stock doses ahead of time rather than requiring fresh preparation for each treatment. Tests confirmed zero T cell contamination in the final batches, addressing a common safety concern about mixed immune cell populations.
Manufacturing Quality and Clinical Readiness
The manufacturing process produced cells with proper maturation markers, ensuring the lab-made cells carried the same weapons that natural NK cells use in the body. By the end of the process, many cells could attack cancer (搜索) cells tagged by antibodies, not just targets they recognized directly.
"Proper maturation ensured the lab-made cells carried the same weapons that natural NK cells use in the body," the researchers noted. The approach maintains cell purity while avoiding mixed lineages that would dilute the final dose and complicate safety assessments.
Implications for Cancer Treatment Accessibility
The breakthrough addresses a critical bottleneck in CAR-NK therapy development. "Repeat infusions can drain cell supplies fast, making consistent manufacturing the real choke point for CAR-NK therapy," the researchers observed. By enabling large-scale production from minimal starting material, this approach could make CAR-NK treatments more predictable and affordable.
The work was supported by the Ministry of Science and Technology of the People's Republic of China and the National Natural Science Foundation of China. While promising, the researchers acknowledge that human trials will be necessary to confirm safety, durability, and clinical efficacy before this manufacturing advance can translate into routine patient care.